Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None2021202020192018201720162015 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021 Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 08/12/2021 Poseida Therapeutics Appoints Cynthia Collins to Board of Directors 07/26/2021 Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders 06/02/2021 Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 05/11/2021 Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting 05/11/2021 Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board 05/06/2021 Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference 05/05/2021 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page next › Last page last » Displaying 1 - 10 of 75
Year None2021202020192018201720162015 Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences 09/07/2021 Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021 Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021 Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 08/12/2021 Poseida Therapeutics Appoints Cynthia Collins to Board of Directors 07/26/2021 Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders 06/02/2021 Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 05/11/2021 Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting 05/11/2021 Poseida Therapeutics Announces Key Additions to Immuno-Oncology Scientific Advisory Board 05/06/2021 Poseida Therapeutics to Present at BofA Securities 2021 Virtual Health Care Conference 05/05/2021 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page next › Last page last » Displaying 1 - 10 of 75
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit 08/31/2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma 08/30/2021
Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 08/12/2021
Poseida Therapeutics Reports Program Updates and Financial Results for the First Quarter 2021 05/11/2021
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T and Gene Therapy Programs at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting 05/11/2021